These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1237 related articles for article (PubMed ID: 29237833)

  • 1. Neutralizing Activity of Broadly Neutralizing Anti-HIV-1 Antibodies against Clade B Clinical Isolates Produced in Peripheral Blood Mononuclear Cells.
    Cohen YZ; Lorenzi JCC; Seaman MS; Nogueira L; Schoofs T; Krassnig L; Butler A; Millard K; Fitzsimons T; Daniell X; Dizon JP; Shimeliovich I; Montefiori DC; Caskey M; Nussenzweig MC
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.
    Stefic K; Bouvin-Pley M; Essat A; Visdeloup C; Moreau A; Goujard C; Chaix ML; Braibant M; Meyer L; Barin F
    J Virol; 2019 Jan; 93(2):. PubMed ID: 30404804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments.
    Hraber P; Rademeyer C; Williamson C; Seaman MS; Gottardo R; Tang H; Greene K; Gao H; LaBranche C; Mascola JR; Morris L; Montefiori DC; Korber B
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
    Li H; Zony C; Chen P; Chen BK
    J Virol; 2017 May; 91(9):. PubMed ID: 28148796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies.
    Wang H; Yuan T; Li T; Li Y; Qian F; Zhu C; Liang S; Hoffmann D; Dittmer U; Sun B; Yang R
    Arch Virol; 2018 Dec; 163(12):3303-3315. PubMed ID: 30196320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
    Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Novel Structural Determinants in MW965 Env That Regulate the Neutralization Phenotype and Conformational Masking Potential of Primary HIV-1 Isolates.
    Qualls ZM; Choudhary A; Honnen W; Prattipati R; Robinson JE; Pinter A
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing Activity of Broadly Neutralizing anti-HIV-1 Antibodies against Primary African Isolates.
    Lorenzi JCC; Mendoza P; Cohen YZ; Nogueira L; Lavine C; Sapiente J; Wiatr M; Mugo NR; Mujugira A; Delany S; Lingappa J; Celum C; Seaman MS; Caskey M; Nussenzweig MC
    J Virol; 2021 Mar; 95(5):. PubMed ID: 33298542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
    Fetzer I; Davis-Gardner ME; Gardner MR; Alfant B; Weber JA; Prasad NR; Zhou AS; Farzan M
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30541842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
    McGuire AT; Glenn JA; Lippy A; Stamatatos L
    J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Rare Mutation in an Infant-Derived HIV-1 Envelope Glycoprotein Alters Interprotomer Stability and Susceptibility to Broadly Neutralizing Antibodies Targeting the Trimer Apex.
    Mishra N; Sharma S; Dobhal A; Kumar S; Chawla H; Singh R; Das BK; Kabra SK; Lodha R; Luthra K
    J Virol; 2020 Sep; 94(19):. PubMed ID: 32669335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
    Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies.
    deCamp A; Hraber P; Bailer RT; Seaman MS; Ochsenbauer C; Kappes J; Gottardo R; Edlefsen P; Self S; Tang H; Greene K; Gao H; Daniell X; Sarzotti-Kelsoe M; Gorny MK; Zolla-Pazner S; LaBranche CC; Mascola JR; Korber BT; Montefiori DC
    J Virol; 2014 Mar; 88(5):2489-507. PubMed ID: 24352443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
    Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R; Louder MK; Wagh K; Bailer RT; deCamp A; Greene K; Gao H; Taft JD; Gazumyan A; Liu C; Nussenzweig MC; Korber B; Montefiori DC; Mascola JR
    J Virol; 2015 Mar; 89(5):2659-71. PubMed ID: 25520506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
    Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
    J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.
    Crooks ET; Grimley SL; Cully M; Osawa K; Dekkers G; Saunders K; Rämisch S; Menis S; Schief WR; Doria-Rose N; Haynes B; Murrell B; Cale EM; Pegu A; Mascola JR; Vidarsson G; Binley JM
    PLoS Pathog; 2018 May; 14(5):e1007024. PubMed ID: 29718999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies.
    LaBranche CC; McGuire AT; Gray MD; Behrens S; Kwong PDK; Chen X; Zhou T; Sattentau QJ; Peacock J; Eaton A; Greene K; Gao H; Tang H; Perez LG; Chen X; Saunders KO; Kwong PD; Mascola JR; Haynes BF; Stamatatos L; Montefiori DC
    PLoS Pathog; 2018 Nov; 14(11):e1007431. PubMed ID: 30395637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.